Labcorp (LH) announced the nationwide availability of Agilent Technologies’ (A) PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. FDA to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck’s (MRK) Keytruda and Keytruda Qlex the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp announces launch of Labcorp Fentanyl Urine Visual Test
- Labcorp launches new AI-powered real-world data platform with AWS
- Labcorp Declares Quarterly Cash Dividend, Signals Ongoing Confidence
- Labcorp price target raised to $300 from $280 at Evercore ISI
- Labcorp Sets Date for First-Quarter 2026 Results